Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.6%

1 terminated/withdrawn out of 18 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

33%

6 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
8(44.4%)
Phase 3
6(33.3%)
N/A
3(16.7%)
Phase 1
1(5.6%)
18Total
Phase 2(8)
Phase 3(6)
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT07736950Phase 3Not Yet Recruiting

A Randomised Phase 3 Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

Role: lead

NCT06664879Phase 1Active Not Recruiting

ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

Role: collaborator

NCT04685616Phase 3Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Role: collaborator

NCT05583552Phase 2Active Not Recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Role: collaborator

NCT05180097Phase 2Recruiting

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Role: collaborator

NCT00049595Phase 3Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Role: collaborator

NCT01843868Not ApplicableWithdrawn

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Role: lead

NCT02001818Phase 2Completed

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

Role: lead

NCT06287398Phase 2Recruiting

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

Role: lead

NCT05833763Phase 2Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Role: lead

NCT00115700Phase 3Completed

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Role: collaborator

NCT00004179Phase 3Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Role: collaborator

NCT00342316Not ApplicableCompleted

Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia

Role: collaborator

NCT00377195Phase 2Unknown

Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma

Role: collaborator

NCT00140582Phase 3Completed

Primary Rituximab and Maintenance

Role: collaborator

NCT00193973Phase 2Completed

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

Role: collaborator

NCT00053092Phase 2Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Role: collaborator

NCT00141648Not ApplicableCompleted

Chemotherapy and Radiotherapy for Osteolymphoma

Role: collaborator

All 18 trials loaded